Sign up for updates

Interested in more information about AMVUTTRA®?

Enter your contact information to stay informed.

By signing up, you’ll receive relevant information to help you guide your patients.

*Indicates required field

Please correct the errors highlighted in red

Interested in more information about AMVUTTRA™?

Enter your contact information to stay informed.

By signing up, you’ll receive relevant information to help you guide your patients.

I am a*

First name*

Last name*

Email address*

Zip code*

Medical specialization*

Professional designation*

I am a US resident and would like to receive updates from Alnylam Pharmaceuticals.*

By submitting this form, I agree to the Alnylam Privacy Policy and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.*

I would like to speak with an Alnylam representative.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

Indication

AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

For patients

Sign up for updates

Interested in more information about AMVUTTRA®?

Enter your contact information to stay informed.

Interested in more information about AMVUTTRA™?

Enter your contact information to stay informed.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Adverse Reactions

Indication

For additional information about AMVUTTRA, please see the full Prescribing Information.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Adverse Reactions

Indication

For additional information about AMVUTTRA, please see the full Prescribing Information.

The site you are about to enter is intended for US healthcare professionals.

You are now leaving www.amvuttrahcp.com.

You are now leaving www.amvuttrahcp.com.

This email address is already in use.

Email sent!